Replies to post #173156 on Biotech Values

[biotech jim]

Re PPARgamma

This is a very impressive Molecular Pharmacology paper you linked for us. As I have said in the past, both here and on SI, all agonists are not created equal. Regarding both partial agonists and full agonists there can be substantial differences in desirable effects and side effects. The effort and resources expended by MRK in a paper like this are absolutely tremendous. I wish they would have detailed the gene ontologies for both cardiac toxicity and for oncologic potential.

If I were interested in GFT505, I would be asking them about how they think that their compound would profile in such a study, what their animal tox looks like when one considers tox animal drug levels compared to actual therapeutic levels, and how they will navigate the FDA concerns.